An updated analysis performed by the Women's Health Initiative revealed that menopausal hormone therapy with estrogen and progestin can significantly increase a woman's risk of death from several types of cancers, including colorectal cancer, according to the study's abstract.
Specifically, WHI found there was a 54 percent increased risk of death after a colorectal cancer diagnosis when female patients were randomized to combined hormone therapy compared to placebo trials. Although a few number of colorectal cancers resulted from the combined-therapy group, the group was at higher risk of mortality.
Read the abstract on menopausal hormone therapy and CRC.
Read other coverage about colorectal cancer:
- Studies Show Mailed and Electronic Reminders Increase Colorectal Cancer Screening Rates
- Study Suggests Hormone Therapy Could Increase Risk of CRC by Up To 40%
- 10 Recent Studies and Breakthroughs Impacting Gastroenterology/Endoscopy
Specifically, WHI found there was a 54 percent increased risk of death after a colorectal cancer diagnosis when female patients were randomized to combined hormone therapy compared to placebo trials. Although a few number of colorectal cancers resulted from the combined-therapy group, the group was at higher risk of mortality.
Read the abstract on menopausal hormone therapy and CRC.
Read other coverage about colorectal cancer:
- Studies Show Mailed and Electronic Reminders Increase Colorectal Cancer Screening Rates
- Study Suggests Hormone Therapy Could Increase Risk of CRC by Up To 40%
- 10 Recent Studies and Breakthroughs Impacting Gastroenterology/Endoscopy